Alzheimer Drug Plus SSRI May Improve Depression/Cognition

By |2019-03-06T13:40:42-08:00March 6th, 2019|Brief Bulletins from the Field, Uncategorized, We Know Psychiatry|

Adding the Alzheimer drug memantine (Namenda, Allergan) to treatment with a selective serotonin reuptake inhibitor may improve depressive symptoms, executive function, and other outcomes in older patients with both depression and cognitive complaints, new research suggests. The findings were presented at the American Association of Geriatric Psychiatry (AAGP) 2019. In a [...]

Three-year Naturalistic Study On Early Use Of Long-acting Injectable Antipsychotics In First Episode Psychosis

By |2018-06-08T16:47:33-07:00May 24th, 2018|Uncategorized|

By Sofia Medrano, Amal Abdel-Baki, Emmanuel Stip, and Stéphane Potvin Abstract Poor adherence to antipsychotics, which affects outcome, is frequent in first episode psy- chosis (FEP). Most randomized studies demonstrate no superiority of long-acting injectable antipsychotics (LAI-AP) over oral antipsychotics (OAP). However, participants in these stud- ies represent a minority of patients [...]

An Interesting Presentation About Cyclical Menstrual Psychosis with an Updated Review of Literature

By |2018-06-08T16:48:07-07:00May 24th, 2018|Uncategorized|

By Marcela Almeida and Heather Burrell-Ward To the editor, We read with great interest the article by S. Thippaiah and colleagues in a recent issue of the journal. The authors reported the interesting case of a 19-year-old woman who presented with cyclical changes in mood and behavior, alternating between depression and [...]

A Case Of Hyper Sexuality Associated With Clozapine

By |2018-06-08T16:48:14-07:00April 20th, 2018|Uncategorized|

By Sereen Rose Thomson, Navin Patil, Balaji Ommurugan, and Rajesh Krishna Bhandary Abstract Schizophrenia treatment needs to cover several psychological interventions and pharmacological treatment for stabilizing the disease course and decreasing relapses. Sexual side effects are a major hindrance to patients and lead to decreased adherence to therapy and reduced quality of life. Recently, [...]

Induction Of Psychosis By Cyclobenzaprine

By |2018-06-08T16:48:20-07:00April 20th, 2018|Uncategorized|

By Johan Y. Cohen and Amélie Guilbault Abstract Due to the stringent regulatory environment for therapeutics, common side-effects of drugs in the general population are largely well-documented. This is however less the case with certain patient subgroups who may exhibit significant adverse responses to therapeutics that are otherwise well-tolerated. We [...]

Letter To The Editor: A Perspective On Adolescent Chronic Pain Dismissal

By |2018-06-08T16:48:25-07:00April 20th, 2018|Uncategorized|

By Jacquelin Peck, MD, and Omar Viswanath, MD ABSTRACT Optimal management of chronic pain is complex and often daunting. In the pediatric and adolescent population, care-givers face additional biases in the face of youth and perceived states of health, which compounds this challenge and frequently leads to dismissal or under-treatment of [...]

Title

Go to Top